Appendix 4C and Quarterly Activities Report - June 2026
Filed with ASX · · 9 pages · English
Imagion Biosystems Ltd. on 6ix
Story so far
Earlier from Imagion Biosystems
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- IBX Secures Firm Commitments for $3.75m for Clinical Trial
- Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
- Imagion Biosystems Receives IND Clearance from US FDA
- Appendix 4C and Quarterly Activities Report - March 2026
Later from Imagion Biosystems
- IBX Phase 2 Clinical Trial Update
- MagSense Nanoparticle Manufacturing Update
- Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities
- IBX Secures Central Ethics Approval - Key Phase 2 Milestone
- Appendix 4C and Quarterly Activities Report - September 2026
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems